Naltrexone was effective in achieving abstinence, reducing lapses and improving craving scores at 3 months in patients with alcohol-related cirrhosis, according to data presented at EASL Congress. “In the largest randomized controlled trial available to date, which is a combined trial with 1,380 patients with alcohol use disorder, naltrexone has been shown to have an increased incidence of